Rodolfo Nunez-Musa*

Contract Research Organization DR (CREOR), MSc, Senior Researcher, Clinical Coordinator at Oy Med School of Medicine, Dominican Republic

*Corresponding Author: Rodolfo Nunez-Musa, Contract Research Organization DR (CREOR), MSc, Senior Researcher, Clinical Coordinator at Oy Med School of Medicine, Dominican Republic..

Received: May 13, 2025; Published: May 26, 2025

Abstract

In the setting of peripheral insulin resistance (IR) characteristic of diabetes, vascular dysfunction and atherosclerotic lesions result from the loss of insulin signaling in the endothelium [1]. Some authors have suggested that the implementation of pharmacological strategies that allow the control of endothelial changes can block vascular inflammation and oxidative stress (OS) and thus prevent metabolic disorders. This action may guarantee the physiological release of oxide nitric acid (NO) and capillary reorganization, as well as greater delivery and better tissue insulin sensitivity, improving the evolution of the disease and reducing the impact or appearance of complications, such as the cardiovascular [2-4]. This is so because the role of genetic alterations induced by factors of a highly varied nature, such as the NF-kB transcription factor in OS, vascular dysfunction, inflammation, and even reduced glucose uptake by some tissues, is shown to be determinants and, therefore, axial in deciding the type of intervention in type 2 diabetes mellitus (T2DM) [5,6].

Keywords: Diabetes Mellitus; Cardiovascular Disease; Unraveling; Interplay

References

1. Gage MC., et al. “Endothelium-specific insulin resistance leads to accelerated atherosclerosis in areas with disturbed flow patterns: A role for reactive oxygen species”. Atherosclerosis 1 (2013): 131-139.
2. Muniyappa R., et al. “Endothelial dysfunction due to selective insulin resistance in vascular endothelium: Insights from mechanistic modeling”. American Journal of Physiology-Endocrinology and Metabolism 319.3 (2020).
3. Takeda Y., et al. “Endothelial dysfunction in diabetes”. Biomedicines7 (2020): 182.
4. Wei Y., et al. “Acacetin improves endothelial dysfunction and aortic fibrosis in insulin-resistant SHR rats by estrogen receptors”. Molecular Biology Reports 9 (2020): 6899-6918.
5. Hasegawa Y., et al. “Blockade of the nuclear factor-ΚB pathway in the endothelium prevents insulin resistance and prolongs life spans”. Circulation 9 (2012): 1122-1133.
6. Kubota T., et al. “Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle”. Cell Metabolism 13.3 (2011): 294-307.v
7. Ke C., et al. “Trends in the association between diabetes and Cardiovascular Events, 1994-2019”. JAMA 328.18 (2022): 1866.
8. Ozkor MA and Quyyumi AA. “Endothelium-derived hyperpolarizing factor and vascular function. Cardiology Research and Practice (2012): 1-12.
9. Al-Qaisi M. “Measurement of endothelial function and its clinical utility for cardiovascular risk”. Vascular Health and Risk Management 4 (2008): 647-652.
10. Wils J., et al. “Modulating putative endothelial progenitor cells for the treatment of endothelial dysfunction and cardiovascular complications in diabetes. Pharmacology and amp; Therapeutics 170 (2017): 98-115.
11. Curtis AM., et al. “Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population”. Cytometry Part B: Clinical Cytometry 5 (2006): 329-337.
12. Deng F., et al. “Endothelial microparticles act as novel diagnostic and therapeutic biomarkers of diabetes and its complications: A literature review”. BioMed Research International (2016): 1-8.
13. Nomura S., et al. “Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes. Journal of Atherosclerosis and Thrombosis 2 (2009): 83-90.
14. Gómez-Marcos MA., et al. “Serum superoxide dismutase is associated with vascular structure and function in hypertensive and diabetic patients”. Oxidative Medicine and Cellular Longevity (2016): 1-8.
15. Kim J., et al. “Reciprocal relationships between insulin resistance and endothelial dysfunction”. Circulation 15 (2006): 1888-1904.
16. Crabtree MJ and Channon KM. “Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease”. Nitric Oxide 25.2 (2011): 81-88.
17. Sibal L., et al. “The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease”. Current Cardiology Reviews 6.2 (2010): 82-90.
18. Kobayashi T., et al. “Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK”. British Journal of Pharmacology 7 (2008): 974-983.
19. Goncharov NV., et al. “Markers and biomarkers of endothelium: When something is Rotten in the State”. Oxidative Medicine and Cellular Longevity (2017): 1-27.
20. Hamilton SJ and Watts GF. “Endothelial dysfunction in diabetes: Pathogenesis, significance, and treatment”. The Review of Diabetic Studies 10.2-3 (2013): 133-156.
21. Woodman RJ., et al. “Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus”. Drugs 1 (2005): 31-74.
22. Haffner SM., et al. “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction”. New England Journal of Medicine 339.4 (1998): 229-234.
23. Bertoluci MC and Rocha VZ. “Cardiovascular risk assessment in patients with diabetes. Diabetology and Metabolic Syndrome1 (2017).
24. Grundy SM., et al. “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines”. Circulation 25 (2012).
25. Skyler JS., et al. “iIntensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, advance, and VA diabetes trials”. Journal of the American College of Cardiology3 (2012): 298-304.
26. Madonna R., et al. “Impact of sex differences and diabetes on coronary atherosclerosis and ischemic heart disease”. Journal of Clinical Medicine 1 (2019): 98.
27. Braun T., et al. “Detection of myocardial ischemia due to clinically asymptomatic coronary artery stenosis at rest using supervised artificial intelligence-enabled vectorcardiography - a five-fold cross validation of accuracy”. Journal of Electrocardiology 59 (2020): 100-105.
28. Gallucci G., et al. “Cardiovascular risk of smoking and benefits of smoking cessation”. Journal of Thoracic Disease 7 (2020): 3866-3876.
29. Qin R., et al. “Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: Meta-analysis of observational prospective studies”. International Journal of Cardiology 2 (2013): 342-350.
30. Pan A., et al. “Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus”. Circulation 19 (2015): 1795-1804.
31. Hartemink N., et al. “Combining risk estimates from observational studies with different exposure cutpoints: A meta-analysis on body mass index and diabetes type 2”. American Journal of Epidemiology 163.11 (2006): 1042-1052.
32. Matheus AS., et al. “Impact of diabetes on cardiovascular disease: An update”. International Journal of Hypertension (2013): 1-15.
33. Rayner JJ., et al. “The relative contribution of metabolic and structural abnormalities to diastolic dysfunction in obesity”. International Journal of Obesity 3 (2012): 441-447.
34. Ofstad AP., et al. “Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls”. Journal of Diabetes 6 (2015): 779-790.
35. Jain V., et al. “IDF21-0582 cardiac structure and function prediabetes and diabetes without heart failure: A hospital based cross-sectional study”. Diabetes Research and Clinical Practice 186 (2022): 109297.
36. From AM., et al. “The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction”. Journal of the American College of Cardiology 55.4 (2010): 300-305.
37. Bobbert, P., et al. “High leptin and resistin expression in chronic heart failure: Adverse outcome in patients with dilated and inflammatory cardiomyopathy”. European Journal of Heart Failure 11 (2012): 1265-1275.
38. Liu W., et al. “Serum leptin, Resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus”. Medicine 99.6 (2020).
39. Waddingham MT. “Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy”. World Journal of Diabetes 7 (2015a): 943.
40. Nielson C and Lange T. “Blood glucose and heart failure in nondiabetic patients”. Diabetes Care 3 (2005): 607-611.
41. Patil VC., et al. “Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function”. Journal of Cardiovascular Disease Research4 (2011): 213-222.
42. Agashe S and Petak, S. (2018). Cardiac autonomic neuropathy in diabetes mellitus”. Methodist DeBakey Cardiovascular Journal 4 (2018): 251.
43. Gæde P., et al. “Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the steno-2 randomised trial”. Diabetologia 59.11 (2016): 2298-2307.
44. Jin J., et al. “Cardiovascular autonomic neuropathy is an independent risk factor for left ventricular diastolic dysfunction in patients with type 2 diabetes”. BioMed Research International (2017): 1-6.
45. Chowdhury M., et al. “Cardiac autonomic neuropathy and risk of cardiovascular disease and mortality in type 1 and type 2 diabetes: A meta-analysis”. BMJ Open Diabetes Research and amp; Care 9.2 (2021).
46. Avogaro A., et al. “Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome”. Diabetes and Vascular Disease Research 5 (2019): 399-414.
47. Marso SP., et al. “Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in st-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD trial)”. The American Journal of Cardiology 2 (2007): 206-210.
48. Miura T and Miki T. “Limitation of myocardial infarct size in the clinical setting: Current status and challenges in translating animal experiments into clinical therapy”. Basic Research in Cardiology 6 (2008): 501-513.
49. Halestrap AP. “A pore way to die: The role of mitochondria in reperfusion injury and cardioprotection”. Biochemical Society Transactions 4 (2010): 841-860.
50. Mazloomzadeh S., et al. “Metabolic syndrome, its components and mortality: A population-based study”. Medical Journal of The Islamic Republic of Iran (2019).
51. Cox AJ., et al. “Glomerular filtration rate and albuminuria predict mortality independently from coronary artery calcified plaque in the diabetes heart study”. Cardiovascular Diabetology 1 (2013).
52. Ramkumar S and Wilson A. “Statins: Review of Safety and potential side effects. Heart, Lung and Circulation (2015): 24.
53. Lam T., et al. “Assessment of Cardiovascular Risk in diabetes: Risk scores and provocative testing”. World Journal of Diabetes4 (2015): 634.
54. Simmons RK., et al. “Performance of the UK prospective diabetes study risk engine and the Framingham risk equations in estimating cardiovascular disease in the epic- Norfolk cohort”. Diabetes Care 32.4 (2008): 708-713.
55. Kengne AP., et al. “The Framingham and UK prospective diabetes study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: The action in diabetes and vascular disease: Preterax and Diamicron-Mr Controlled Evaluation (advance) study”. Diabetologia 5 (2010): 821-831.
56. Saeedi P., et al. “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”. Diabetes Research and Clinical Practice 157 (2019): 107843.

Citation

Citation: Rodolfo Nunez-Musa. “Type 2 Diabetes Mellitus and Cardiovascular Disease: Unraveling the Complex Interplay (Part II of II)".Acta Scientific Nutritional Health 9.6 (2025): 65-75.

Copyright

Copyright: © 2025 Rodolfo Nunez-Musa. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.